Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors.
Rapisuwon S, Izar B, Batenchuk C, Avila A, Mei S, Sorger P, Parks JM, Cooper SJ, Wagner D, Zeck JC, Charabaty AJ, Atkins MB. Rapisuwon S, et al. Among authors: izar b. J Immunother Cancer. 2019 Mar 4;7(1):61. doi: 10.1186/s40425-019-0533-0. J Immunother Cancer. 2019. PMID: 30832716 Free PMC article.
Massively parallel base editing screens to map variant effects on anti-tumor hallmarks of primary human T cells.
Walsh ZH, Shah P, Kothapalli N, Nikolenyi G, Shah SB, Leuzzi G, Mu M, Ho P, Abuzaid S, Brodtman ZD, Vasan N, AlQuraishi M, Milner JD, Ciccia A, Melms JC, Izar B. Walsh ZH, et al. Among authors: izar b. bioRxiv [Preprint]. 2023 Dec 14:2023.12.13.571465. doi: 10.1101/2023.12.13.571465. bioRxiv. 2023. Update in: Nat Biotechnol. 2024 May 23. doi: 10.1038/s41587-024-02235-x PMID: 38168306 Free PMC article. Updated. Preprint.
Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.
Altorki NK, Walsh ZH, Melms JC, Port JL, Lee BE, Nasar A, Spinelli C, Caprio L, Rogava M, Ho P, Christos PJ, Saxena A, Elemento O, Bhinder B, Ager C, Amin AD, Sanfilippo NJ, Mittal V, Borczuk AC, Formenti SC, Izar B, McGraw TE. Altorki NK, et al. Among authors: izar b. Nat Commun. 2024 Jan 3;15(1):225. doi: 10.1038/s41467-023-44575-3. Nat Commun. 2024. PMID: 38172131 Free PMC article. No abstract available.
B-cells Drive Response to PD-1 Blockade in Glioblastoma Upon Neutralization of TGFβ-mediated Immunosuppression.
Hou D, Castro B, Dapash M, Zolp A, Katz J, Arrieta V, Biermann J, Melms J, Kueckelhaus J, Benotmane J, Youngblood M, Rashidi A, Billingham L, Dmello C, Vazquez-Cervantes G, Lopez-Rosas A, Han Y, Patel R, Chia TY, Sun L, Prins R, Izar B, Heiland DH, Zhang P, Sonabend A, Miska J, Lesniak M, Zhao J, Lee-Chang C. Hou D, et al. Among authors: izar b. Res Sq [Preprint]. 2023 Jan 9:rs.3.rs-2399170. doi: 10.21203/rs.3.rs-2399170/v1. Res Sq. 2023. PMID: 36711497 Free PMC article. Preprint.
KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response.
Ager CR, Zhang M, Chaimowitz M, Bansal S, Obradovic A, Rogava M, Melms JC, McCann P, Spina C, Drake CG, Dallos MC, Izar B. Ager CR, et al. Among authors: izar b. bioRxiv [Preprint]. 2023 Jan 2:2023.01.01.522340. doi: 10.1101/2023.01.01.522340. bioRxiv. 2023. Update in: J Immunother Cancer. 2023 Sep;11(9):e006782. doi: 10.1136/jitc-2023-006782 PMID: 36711647 Free PMC article. Updated. Preprint.
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq.
Tirosh I, Izar B, Prakadan SM, Wadsworth MH 2nd, Treacy D, Trombetta JJ, Rotem A, Rodman C, Lian C, Murphy G, Fallahi-Sichani M, Dutton-Regester K, Lin JR, Cohen O, Shah P, Lu D, Genshaft AS, Hughes TK, Ziegler CG, Kazer SW, Gaillard A, Kolb KE, Villani AC, Johannessen CM, Andreev AY, Van Allen EM, Bertagnolli M, Sorger PK, Sullivan RJ, Flaherty KT, Frederick DT, Jané-Valbuena J, Yoon CH, Rozenblatt-Rosen O, Shalek AK, Regev A, Garraway LA. Tirosh I, et al. Among authors: izar b. Science. 2016 Apr 8;352(6282):189-96. doi: 10.1126/science.aad0501. Science. 2016. PMID: 27124452 Free PMC article.
A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status.
Izar B, Sharfman W, Hodi FS, Lawrence D, Flaherty KT, Amaravadi R, Kim KB, Puzanov I, Sosman J, Dummer R, Goldinger SM, Lam L, Kakar S, Tang Z, Krieter O, McDermott DF, Atkins MB. Izar B, et al. Cancer Med. 2017 Aug;6(8):1904-1914. doi: 10.1002/cam4.1140. Epub 2017 Jul 18. Cancer Med. 2017. PMID: 28719152 Free PMC article. Clinical Trial.
98 results